Seres Gets Constructive Feedback From FDA On Phase 2 Study Protocol For SER-155; To Cut Workforce

Seres Therapeutics (MCRB) received constructive FDA feedback on the Phase 2 study protocol for its lead program, SER-155, aimed at preventing bloodstream infections in allogeneic hematopoietic stem cell transplant patients, with positive results potentially enabling a single Phase 3 trial. Concurrently, the company announced a 25% workforce reduction, including prior cuts, incurring $1.0-$1.4 million in Q4 2025 cash payments, a move expected to extend its cash runway well into Q2 2026 as it seeks capital for further development.

Analysis

Seres Therapeutics (MCRB) is in a dichotomous position, marked by positive regulatory progress for its lead asset, SER-155, set against significant financial pressures that necessitate corporate restructuring. The receipt of constructive FDA feedback on the Phase 2 protocol for SER-155 is a key de-risking event, as it could enable a more direct path to registration with a single Phase 3 trial if Phase 2 results are positive. However, this clinical advancement is juxtaposed with the operational reality of a 25% workforce reduction. This cost-cutting measure, which will incur cash payments of $1.0 to $1.4 million, is explicitly designed to extend the company's cash runway well into the second quarter of 2026. This move highlights the company's precarious financial state, as it is simultaneously engaging with multiple parties to secure the necessary capital to advance the very study that just received favorable FDA guidance. The situation presents a clear narrative: the company has a promising clinical pathway but a critical funding gap that it must bridge in the near term.

Key Decisions for Investors

• Investors should prioritize monitoring for news of financing or strategic partnerships, as securing capital for the SER-155 Phase 2 study is the most critical near-term catalyst and a primary risk factor.
• The current investment thesis requires weighing the potential upside from a streamlined regulatory path for SER-155 against the considerable financing and operational risks underscored by the workforce reduction.
• The extended cash runway to Q2 2026 provides a specific timeframe for management to deliver on its capital-raising efforts; failure to secure funding within this window would significantly increase downside risk.